Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial
Lilly added pegilodecakin to its portfolio with the acquisition of Armo BioSciences last year. Credit: Momoneymoproblemz.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
